ARCH:TSXV
ACHFF:OTC
Home
About us
Our story, our approach
Our Science
Pipeline, research & publications
Our Key Platforms
MetaBlok™
Treating, organ injury caused by inflammation
AB569
Treatment for Respiratory Pseudomonas aeruginosa Infections
BORG
Peptide Solid Surface Interface
MetaMx™
Brain Tumor Initiating Cell Targeting
Our Publications
Peer-reviewed scientific publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Management & lead scientists
Our Management
Governance, Executive, Board of Directors and Advisors
Our Principal Scientists
Learn about the scientists behind our technologies
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Investor relations, fundamentals
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us
Material Change Documents
Material Change Documents 2020
Download PDF Documents
Material Change Report 2020-07-06
Material Change Documents 2019
Download PDF Documents
Material Change Report 2019-12-13
Material Change Report 2019-12-23
Material Change Documents 2018
Download PDF Documents
Material Change Report 2018-02-05
Material Change Documents 2017
Download PDF Documents
Material Change Report 2017-03-06
Material Change Report 2017-08-10
Material Change Report 2017-09-20
Material Change Documents 2016
Download PDF Documents
Material Change Report 2016-06-30
Material Change Documents 2015
Download PDF Documents
Material Change Report 2015-01-22
Material Change Documents 2014
Download PDF Documents
Material Change Report 2014-03-05
Material Change Report 2014-04-01
Material Change Report 2014-07-16
Material Change Report 2014-08-18
Material Change Documents 2013
Download PDF Documents
Material Change Report 2013-08-12
Material Change Documents 2012
Download PDF Documents
Material Change Report 2012-04-26
Recent News
September 10th 2020
Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide
Read More
September 1st 2020
Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients
Read More
See All
Subscribe to News
Material Change Documents
Home
About us
Our Science
--Our Key Platforms
---MetaBlok™
---AB569
---BORG
---MetaMx™
--Our Publications
---AB569
---Brain Tumor Stem Cell Targeting
---BORG Peptide Solid Surface Interface
---Treatments for Inflammation
Our Team
--Our Management
--Our Principal Scientists
---MetaBlok™ and MetaMx™
---AB569 & Respiratory Pseudomonas
---BORG Peptide
---Treatments for Inflammation
Investor Hub
--Fundamentals
---Press Releases
---Investor Information
---Stock Performance
--Reports and Filings
---Management Discussion and Analysis
---Annual and Quarterly Reports
---Proxies and Information Circulars
---Material Change Documents
---Other SEDAR Filings
Contact Us
Home
About us
Our Science
Our Key Platforms
MetaBlok™
AB569
BORG
MetaMx™
Our Publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Our Management
Our Principal Scientists
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us